Extrait

To estimate the relative risk of the composite endpoint of Clinical Events Committee (CEC) adjudicated cardiovascular (CV) death or myocardial infarction (MI) through 6 months of maintenance treatment with prasugrel plus aspirin compared to clopidogrel plus aspirin after loading with 600-mg clopidogrel and successful elective PCI with placement of at least one drug-eluting stent (DES) in subjects with high platelet reactivity as assessed by the VerifyNow® device (P2Y12 reaction units [PRU] >208) after the first MD (75-mg) of clopidogrel. The intent of this study is to demonstrate that prasugrel is superior to clopidogrel in preventing the composite endpoint in this population.

Critère d'inclusion

• Reduction of composite cardio-vascular end-point in patients who have successfully undergone elective percutaneous coronary intervention with placement of at least one drug-eluting stent

Liens

• ictrp
• euctr